Flen Health is a privately held, family-owned biopharmaceutical company headquartered in Kontich, Belgium. Founded in 2000 by pharmacist Philippe Sollie as Flen Pharma and later rebranded, it specializes in the development and commercialization of innovative wound and skin healing solutions.
The company focuses on advanced topical therapies based on proprietary enzyme technology, including enzyme-alginate gels that modulate inflammation, eliminate microorganisms, and promote healing in chronic and difficult-to-heal wounds such as diabetic foot ulcers, venous leg ulcers, and severe burns. Key products include Flaminal (Hydro and Forte), Flamigel, Flamirins, and Extracalm, which have been used clinically in Europe for over 25 years as medical devices.
Flen Health operates affiliates in Belgium, Luxembourg, the Netherlands, Germany, the UK, Ireland, Italy, and the US, with products distributed in more than 40 countries worldwide. It employs over 110 people and is actively transitioning toward biopharmaceutical development, including recombinant enzyme platforms for next-generation therapies targeting the US market through clinical trials and regulatory submissions.
As a family enterprise, it maintains a strong emphasis on patient-centric innovation, R&D (with significant external grants), and global expansion while remaining privately owned.
Also known as Flen Pharma and Flen Health Pharma.
None yet. When a new project in the record names Flen Health as owner, partner or investor, it shows here.
Process development and GMP manufacturing of lactoperoxidase and glucose oxidase to support an IND filing and a Phase II clinical trial in the US.
